CAPR
NASDAQCapricor Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$7.26+0.50 (+7.47%)
01:30 PM07:45 PM
News · 26 weeks49-83%
2026-04-192026-10-11
Mix2890d
- Analyst13(46%)
- Other8(29%)
- SEC Filings5(18%)
- Earnings2(7%)
Latest news
25 items- PRCapricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data fr
- PRCapricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company’s lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31st Annual Congress of the World Muscle Society (
- ANALYSTCapricor Therapeutics upgraded by B. Riley Securities with a new price targetB. Riley Securities upgraded Capricor Therapeutics from Neutral to Buy and set a new price target of $21.00
- ANALYSTCapricor Therapeutics upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Capricor Therapeutics from Neutral to Overweight and set a new price target of $25.00
- ANALYSTCapricor Therapeutics upgraded by Oppenheimer with a new price targetOppenheimer upgraded Capricor Therapeutics from Perform to Outperform and set a new price target of $54.00
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRCapricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), from August 22, 2026 to November 22, 2026. As part of its on
- SECSEC Form 10-Q filed by Capricor Therapeutics Inc.10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRThese Biotech Breakouts and Squeeze Setups Could Be Just Getting StartedDENVER, Aug. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics (NASDAQ:CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Onfolio Holdings (NASDAQ:ONFO) is a structure-sensitive short squeeze. NeOnc Technologies Holdings: Phase 2a Data Put NEO100 at the Center of the Story NeOnc (NASDAQ:NTHI) is the clear fundamental headline among this group. The company’s NEO100 Phase 2a readout
- ANALYSTCapricor Therapeutics upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded Capricor Therapeutics from Neutral to Overweight and set a new price target of $28.00
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRCapricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateDeramiocel Biologics License Application (BLA) under active FDA reviewHOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029Cash, cash equivalents and marketable securities of approximately $238 million as of June 30, 2026 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. "Our priority is, and always has been, to get Deram
- PRCapricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 13, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics Second Quarter 2026 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Thursday, August 13, 2026Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 91880P
- SECSEC Form SCHEDULE 13G filed by Capricor Therapeutics Inc.SCHEDULE 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for DeramiocelSAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a rare and life-threatening disease for which no approved cardiomyopathy treatment currently exists (3 for, 9 against, 0 abstain). The Committee's vote is non-binding. The Committee's voting question addressed a narrower indicat
- ANALYSTCapricor Therapeutics downgraded by Maxim GroupMaxim Group downgraded Capricor Therapeutics from Buy to Hold
- ANALYSTCapricor Therapeutics downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded Capricor Therapeutics from Overweight to Neutral and set a new price target of $3.50
- ANALYSTCapricor Therapeutics downgraded by OppenheimerOppenheimer downgraded Capricor Therapeutics from Outperform to Perform
- ANALYSTCapricor Therapeutics downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Capricor Therapeutics from Overweight to Neutral and set a new price target of $2.00
- ANALYSTCapricor Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Capricor Therapeutics from Buy to Neutral
- ANALYSTCapricor Therapeutics downgraded by Ladenburg ThalmannLadenburg Thalmann downgraded Capricor Therapeutics from Buy to Neutral
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit-- --Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026-- SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that The Lancet, one of t
- ANALYSTCapricor Therapeutics downgraded by Alliance Global Partners with a new price targetAlliance Global Partners downgraded Capricor Therapeutics from Buy to Neutral and set a new price target of $7.00
CAPR FAQ
6 questionsWhat does Capricor Therapeutics Inc. do?
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment...Where does CAPR stock trade?
Capricor Therapeutics Inc. (CAPR) is listed on NASDAQ.What sector and industry is CAPR in?
Capricor Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CAPR?
Capricor Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $2100.00 price target on 2026-09-14.What companies are similar to CAPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CAPR side-by-side with any of them on Quantisnow.How can I track CAPR on Quantisnow?
Quantisnow aggregates Capricor Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAPR to receive live email and push alerts on every new disclosure.